rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2011-7-2-231-240rpcardio-755Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИLIPRIMAR®. FIFTEEN YEARS OF EVIDENCEЛИПРИМАР®. ПЯТНАДЦАТЬ ЛЕТ УБЕДИТЕЛЬНЫХ ДОКАЗАТЕЛЬСТВСусековА. В.SusekovA. V.

д.м.н., в.н.с. отдела возрастных проблем сердечно-сосудистых заболеваний

asus99@mail.ruХохловаН. В.KhokhlovaN. V.

аспирант отдела возрастных проблем сердечно-сосудистых заболеваний

Институт клинической кардиологии им. А.Л. Мясникова, Российский кардиологический научно-производственный комплексРоссияInstitute for Cardiology named after A.L. Mjasnikov , Russian Cardiology Research and Production ComplexRussian Federation20111401201672231240Copyright © Susekov A.V., Khokhlova N.V., 20162016Сусеков А.В., Хохлова Н.В.Susekov A.V., Khokhlova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/755

The evidences for statin use in cardiology are presented. Especially hypolipidemic efficacy of atorvastatin is demonstrated in according to comparative studies. Results of clinical studies on atorvastatin efficacy and safety in different groups of patients are also presented.

Приводятся доказательства по применению статинов в кардиологии. Отдельно расcматривается гиполипидемическая эффективность аторвастатина, продемонстрированная в сравнительных исследованиях. Также приводятся клинические исследования эффективности и безопасности аторвастатина в различных группах больных.

статиныаторвастатинатеросклерозклинические исследованияstatinsatorvastatinatherosclerosisclinical trialsReferencesExpert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.National guidelines for diagnosis and correction of disorders of lipid metabolism in order to prevent and treat atherosclerosis. Kardiovaskulyarnaya terapiya i profilaktika 2007;6 (6) Prilozhenie 3: 1-35. Rusian (Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007;6 (6) Приложение 3: 1-35).National guidelines for diagnosis and correction of disorders of lipid metabolism in order to prevent and treat atherosclerosis. Kardiovaskulyarnaya terapiya i profilaktika 2007;6 (6) Prilozhenie 3: 1-35. Rusian (Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика 2007;6 (6) Приложение 3: 1-35).Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44(3):720-32Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44(3):720-32Fourth Joint Task Force of the European Society of cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (Constituted by reprtesentatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:S1-113.Fourth Joint Task Force of the European Society of cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (Constituted by reprtesentatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:S1-113.Genest J., McPherson R., Frohlich J. et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25(10):567-79.Genest J., McPherson R., Frohlich J. et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25(10):567-79.Jones P, Kafonek S., Laurora I., Hunninghake D., for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiology 1998:81(5):582-587.Jones P, Kafonek S., Laurora I., Hunninghake D., for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiology 1998:81(5):582-587.Pitt B., Waters D., Brown W.V. et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-76.Pitt B., Waters D., Brown W.V. et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-76.Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–1718.Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711–1718.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9McCormick L.S., Black D.M., Waters D. et al. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am J Cardiol 1997;80:1130-3.McCormick L.S., Black D.M., Waters D. et al. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am J Cardiol 1997;80:1130-3.Smilde T.J., van Wissen S., Wollersheim H. et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577–81Smilde T.J., van Wissen S., Wollersheim H. et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577–81Sever P.S., Poulter N.R., Dahlöf B. et al. Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96: 39F–44FSever P.S., Poulter N.R., Dahlöf B. et al. Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96: 39F–44FColhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96Colhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24:1335–1341,The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia The DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24:1335–1341,Okazaki S., Yokoyama T., Miyauchi K. et al. Early Statin Treatment in Patients With Acute Coronary Syndrome Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004;110:1061-1068.Okazaki S., Yokoyama T., Miyauchi K. et al. Early Statin Treatment in Patients With Acute Coronary Syndrome Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004;110:1061-1068.Athyros V.G., Mikhailidis D.P., Papageorgiou A.A. et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart- disease Evaluation (GREACE) Study. Curr Med Res Opin 2004; 20(5): 627-637Athyros V.G., Mikhailidis D.P., Papageorgiou A.A. et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart- disease Evaluation (GREACE) Study. Curr Med Res Opin 2004; 20(5): 627-637Pedersen T.R., Faergeman O., Kastelein J.J. et al. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: A Randomized Controlled Trial. JAMA 2005;294:2437-2445Pedersen T.R., Faergeman O., Kastelein J.J. et al. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: A Randomized Controlled Trial. JAMA 2005;294:2437-2445Amarenco P., Bogousslavsky J., Callahan A. 3rd et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL). N Engl J Med 2006;355:549-59.Amarenco P., Bogousslavsky J., Callahan A. 3rd et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL). N Engl J Med 2006;355:549-59.Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22. N Engl J Med 2004;350:1495-504.Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22. N Engl J Med 2004;350:1495-504.Nissen S.E., Tuzcu E.M., Schoenhagen P. et al REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 3; 291(9):1071-80.Nissen S.E., Tuzcu E.M., Schoenhagen P. et al REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 3; 291(9):1071-80.LaRosa J.C., Grundy S.M., Waters D.D. et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35.LaRosa J.C., Grundy S.M., Waters D.D. et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35.Nawrocki J.W., Weiss S.R., Davidson M.H. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology 1995; 15:678-682.Nawrocki J.W., Weiss S.R., Davidson M.H. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology 1995; 15:678-682.Pedersen T.R., Faergeman O, Kastelein JJP et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294(19):2437-2445Pedersen T.R., Faergeman O, Kastelein JJP et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294(19):2437-2445Jones P.H., Davidson M.H., Stein E.A. et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92(2):152-60Jones P.H., Davidson M.H., Stein E.A. et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92(2):152-60Nawrocki J.W., Weiss S.R., Davidson M.H. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology 1995; 15:678-682.Nawrocki J.W., Weiss S.R., Davidson M.H. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology 1995; 15:678-682.Andrews T.C., Ballantyne C.V., Hsia J.A. et al. Achieving and maintaining National Cholesterol Education Program low–density lipoprotein cholesterol goals with five statins. Am J Med; 111(3);185–91.Andrews T.C., Ballantyne C.V., Hsia J.A. et al. Achieving and maintaining National Cholesterol Education Program low–density lipoprotein cholesterol goals with five statins. Am J Med; 111(3);185–91.Conclusion Expert Society of Cardiology of the Russian Federation, Russian National Society of Atherosclerosis, Russian Society cardiosomatic rehabilitation and secondary prevention to optimize statin therapy in clinical practice. Rational Pharmacother Card 2011; 7 (1) :107-109 Russian (Заключение экспертов ВНОК, НОА, РОСОКР по оптимизации терапии статинами в клинической практике. РФК 2011; 7(1):107-109)Conclusion Expert Society of Cardiology of the Russian Federation, Russian National Society of Atherosclerosis, Russian Society cardiosomatic rehabilitation and secondary prevention to optimize statin therapy in clinical practice. Rational Pharmacother Card 2011; 7 (1) :107-109 Russian (Заключение экспертов ВНОК, НОА, РОСОКР по оптимизации терапии статинами в клинической практике. РФК 2011; 7(1):107-109)Karalis D.G., Ross A.M., Vacari R.M. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002;89(6): 667–71.Karalis D.G., Ross A.M., Vacari R.M. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002;89(6): 667–71.Jones P.H., McKenney J.M., Karalis D.G. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evide Based Cardiovasc Med 2005; 9(2):98– 101.Jones P.H., McKenney J.M., Karalis D.G. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evide Based Cardiovasc Med 2005; 9(2):98– 101.Schrott H., Fereshetian A.G., Knopp R.H. et al. A Multicenter, Placebo–Controlled, Dose– Ranging Study of Atorvastatin. J Cardiovasc Pharmacol Ther 1998; 3(2):119–124.Schrott H., Fereshetian A.G., Knopp R.H. et al. A Multicenter, Placebo–Controlled, Dose– Ranging Study of Atorvastatin. J Cardiovasc Pharmacol Ther 1998; 3(2):119–124.Michael J., Haller1., Jennifer M. et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): A Pilot Study to Determine the Effect of Atorvastatin on Arterial Stiffness and Endothelial Function in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology & Metabolism 2009; 22: 65-68Michael J., Haller1., Jennifer M. et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): A Pilot Study to Determine the Effect of Atorvastatin on Arterial Stiffness and Endothelial Function in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology & Metabolism 2009; 22: 65-68Pfizer Inc. Data on file. New York, NY; 2002.Pfizer Inc. Data on file. New York, NY; 2002.Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-372.7.Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-372.7.McTaggrat F., Buckert L., Davidson R.. et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiology 2001: 87 (Suppl): 28B-32BMcTaggrat F., Buckert L., Davidson R.. et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiology 2001: 87 (Suppl): 28B-32BHoldgate G.A., Ward W.H., McTaggart F.. Molecular mechanism for inhibition of 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003; 31(Pt 3):528-31.Holdgate G.A., Ward W.H., McTaggart F.. Molecular mechanism for inhibition of 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 2003; 31(Pt 3):528-31.Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G. et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001;158(1):183-93.Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G. et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001;158(1):183-93.Barter P.J., Brandrup-Wognsen G., Palmer M.K. et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010;51(6):1546-53Barter P.J., Brandrup-Wognsen G., Palmer M.K. et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010;51(6):1546-53Stein E.A. Adult treatment panel III and the management of dyslipidemia risk factors. Postgrad Med 2002;112(4 Suppl):12-7.Stein E.A. Adult treatment panel III and the management of dyslipidemia risk factors. Postgrad Med 2002;112(4 Suppl):12-7.Nicholls S.J, Tuzcu E.M., Sipahi I. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297(5):499-508Nicholls S.J, Tuzcu E.M., Sipahi I. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297(5):499-508Insull W., Kafonek S., Goldner D., Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol 2001;87:554-559Insull W., Kafonek S., Goldner D., Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol 2001;87:554-559Martineau P., Gaw A., de Teresa E. et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Atherosclerosis. 2007 Mar;191(1):135-46.Martineau P., Gaw A., de Teresa E. et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Atherosclerosis. 2007 Mar;191(1):135-46.Briel M., Ferreira-Gonzalez I., You J.J. et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338: b92.Briel M., Ferreira-Gonzalez I., You J.J. et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338: b92.Forrest M.J., Bloomfield D., Briscoe R.J. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. British Journal of Pharmacology 2008; 154: 1465–1473Forrest M.J., Bloomfield D., Briscoe R.J. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. British Journal of Pharmacology 2008; 154: 1465–1473Mullins C.D., Rattinger G.B., Kuznik A., Koren M.J. Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study. Clin Ther 2008;30: 2204-2216Mullins C.D., Rattinger G.B., Kuznik A., Koren M.J. Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study. Clin Ther 2008;30: 2204-2216Athyros V.G., Papageorgiou A.A., Mercouris B.R. et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-228Athyros V.G., Papageorgiou A.A., Mercouris B.R. et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-228Newman C, Tsai J, Szarek M et al. Comparative Safety of Atorvasatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiology 2006; 97:61-67.Newman C, Tsai J, Szarek M et al. Comparative Safety of Atorvasatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiology 2006; 97:61-67.Rozhkova T.A., Susekov A.V., Solov'eva EIu et al. Efficacy and tolerability of statins in patients with primary hyperlipidemias. Kardiologiia 2005;45(9):32-4. Russian (Рожкова Т.А., Сусеков А.В., Соловьева Е.Ю. и др. Эффективность и переносимость статинов у больных с первичными гиперлипидемиями в амбулаторной клинической практике. Кардиология 2005;45(9):32-34).Rozhkova T.A., Susekov A.V., Solov'eva EIu et al. Efficacy and tolerability of statins in patients with primary hyperlipidemias. Kardiologiia 2005;45(9):32-4. Russian (Рожкова Т.А., Сусеков А.В., Соловьева Е.Ю. и др. Эффективность и переносимость статинов у больных с первичными гиперлипидемиями в амбулаторной клинической практике. Кардиология 2005;45(9):32-34).Waters D. Safety of high-dose atorvasatin therapy. Am J cardiology 2005;96 [suppl] 69F-75F.Waters D. Safety of high-dose atorvasatin therapy. Am J cardiology 2005;96 [suppl] 69F-75F.Kanamitsu M., Ebisuzaki W., Woollen J. et al. NCEP-DEO AMIP-II Reanalysis (R-2). Bull of the Atmos Met Soc 2002; 83: 1631-1643.Kanamitsu M., Ebisuzaki W., Woollen J. et al. NCEP-DEO AMIP-II Reanalysis (R-2). Bull of the Atmos Met Soc 2002; 83: 1631-1643.Di Pasquale G. Presentation: European practice guidelines for the prevention of cardiovascular diseases in clinical practice. G Ital Cardiol (Rome) 2008;9(1):9-10.Di Pasquale G. Presentation: European practice guidelines for the prevention of cardiovascular diseases in clinical practice. G Ital Cardiol (Rome) 2008;9(1):9-10.

The authors declare that there are no conflicts of interest present.